IQV Stock Chart & Stats
$3290.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$2,800.00 - $4,461.59
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$607.12B
Enterprise ValueN/A
Total Cash (Recent Filing)$1.95B
Total Debt (Recent Filing)$16.07B
Price to Earnings (P/E)25.6
Beta-0.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.14
Shares Outstanding166,900,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio6.34
Price to Book (P/B)5.96
Price to Sales (P/S)2.38
P/FCF Ratio18.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3,918.48Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent operating cash flow and improving free‑cash‑flow momentum provide durable internal funding for R&D, tech investments, buybacks and debt repayment. High cash conversion versus net income also lends resilience in downturns and supports multi‑year strategic initiatives.
Diversified, Recurring Revenue ModelIQVIA’s mix of CRO services, data/analytics subscriptions and outsourced commercial programs creates recurring revenue streams and cross‑sell opportunities. That breadth reduces single‑market cyclicality, increases client stickiness via long contracts and supports stable multi‑year revenue visibility.
Large Backlog And AI AdoptionA sizable backlog plus rapid AI deployment signals structural demand for analytics and tech‑enabled services. Broad adoption of iqvia.ai by major pharma enhances differentiation, accelerates higher‑margin, recurring tech revenue and strengthens long‑term client engagement and pipeline expansion.
Bears Say
Elevated LeverageSubstantial absolute debt and a ~3.6x net leverage level constrain financial flexibility. Higher leverage increases interest‑rate and refinancing risk, limits capacity for opportunistic M&A or large buybacks, and raises vulnerability if revenue or margins weaken unexpectedly.
Margin Pressure And VolatilityRecent EBITDA compression from FX and mix shows margins are sensitive to pass‑throughs and currency swings. Such structural mix risks — shifting between service‑fee and low‑margin pass‑through work — can depress gross margins and limit sustainable operating‑profit expansion.
Timing And Conversion Risk From FundingA meaningful lag between client funding and contract awards creates timing uncertainty for revenue conversion. Even with strong funding, delayed award cadence and below‑normal pass‑throughs can compress near‑term booked revenue and complicate forecasting over the medium term.
IQVIA Holdings News
IQV FAQ
What was IQVIA Holdings’s price range in the past 12 months?
IQVIA Holdings lowest stock price was $2800.00 and its highest was $4461.59 in the past 12 months.
What is IQVIA Holdings’s market cap?
IQVIA Holdings’s market cap is $607.12B.
When is IQVIA Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were IQVIA Holdings’s earnings last quarter?
Currently, no data Available
Is IQVIA Holdings overvalued?
According to Wall Street analysts IQVIA Holdings’s price is currently Undervalued.
Does IQVIA Holdings pay dividends?
IQVIA Holdings does not currently pay dividends.
What is IQVIA Holdings’s EPS estimate?
IQVIA Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IQVIA Holdings have?
IQVIA Holdings has 166,900,000 shares outstanding.
What happened to IQVIA Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IQVIA Holdings?
Currently, no hedge funds are holding shares in MX:IQV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IQVIA Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3,918.48 (― Downside)
$3,918.48 (― Downside)
Blogger Sentiment
Neutral
MX:IQV Sentiment 50%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.61%
Trailing 12-Months
Company Description
IQVIA Holdings
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
IQV Revenue Breakdown
40.63% Technology & Analytics Solutions
54.54% Research & Development Solutions
4.83% Contract Sales & Medical Solutions
IQV Stock 12 Month Forecast
Average Price Target
$3,918.48